Scientists test new two- and Three-Drug cocktails against tough cancers
NCT ID NCT03502733
Summary
This early-phase study is testing the safety and best doses of combining the cancer drug copanlisib with immunotherapy drugs (nivolumab alone or with ipilimumab). It involves 64 adults with advanced solid tumors or lymphoma that have progressed after standard treatments. The goal is to see if blocking tumor growth pathways with copanlisib while boosting the immune system's attack on cancer is safe and shows early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.